// App-Quantinova.ai

TPS2600 : A phase 1b/2 study of ibrutinib combination therapy in selected advanced genitourinary and gastrointestinal tumors.

Researchers

Presenter

  • Jordan Berlin

Principal Investigators

  • Edwin M. Posadas

  • Teresa Mercade Macarulla

  • Alex Cacovean

  • Karl Eckert

  • Brian Munneke

  • George W. Cole

  • Danelle Frances James

  • Robert J. Motzer

Medical Centers

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Pharmcyclics LLC, an AbbVie Company, Sunnyvale, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Spain

Companies

  • Pharmacyclics LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Metastatic Renal Cell Cancer

  • Metastatic gastric and oesogastric junction (AGC) adenocarcinoma

  • Advanced Urothelial Carcinoma

  • Gastrointestinal stromal tumor

  • Gastric Cancer

  • Bladder Cancer

  • Renal cell carcinoma

  • Solid malignancies

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Everolimus

  • Paclitaxel

  • Erbitux

  • Docetaxel

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • I

Study Id's

  • NCT02599324

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved